Construction of competing endogenous RNA network and identification of novel molecular biomarkers in colon cancer: A bioinformatic analysis.

ABSTRACT: Colon cancer patients suffer from high incidence and mortality rates worldwide. More novel molecular biomarkers should be used for the diagnosis and treatment of colon cancer. Long noncoding RNAs (lncRNAs) are found to be involved in colon cancer tumorigenesis and metastasis. This study aimed to identify novel lncRNAs in colon cancer.Two independent datasets (GSE70880 and GSE110715) were downloaded from the Gene Expression Omnibus database and merged with the sva package. R software was used to distinguish differentially expressed lncRNAs and mRNAs in the merged dataset. The competing endogenous RNA (ceRNA) network was constructed using differentially expressed lncRNAs and mRNAs with Cytoscape. Differentially expressed RNAs in the ceRNA network were further verified using the Cancer Genome Atlas database. Gene oncology analysis, Kyoto Encyclopedia of Genes and Genomes pathway enrichment and survival analysis were also performed to identify hub genes.A total of 99 differentially expressed lncRNAs and 95 differentially expressed mRNAs were identified in the merged database. Ten lncRNAs, 8 miRNAs, and 6 mRNAs were involved in the ceRNA network, in which LINC00114 and UCA1 were highly expressed in colon cancer. They were both associated with early tumor stages and might be used for the early diagnosis of colon cancer. High expression of LINC00114 can lead to poor overall survival of colon cancer patients. Furthermore, new pathways such as LINC00114/miR-107/PCKS5, UCA1/miR-107/PCKS5, and UCA1/miR-129-5p/SEMA6A were identified.Two novel lncRNAs (LINC00114 and UCA1) in colon cancer were identified by bioinformatics analysis. They might contribute to the occurrence and development of colon cancer. In addition, LINC00114 may be involved in the overall survival of colon cancer patients.

Effect of fluoxetine intervention on clinical efficacy and neurological function rehabilitation in patients with depression after cerebral infarction / 中国基层医药

Objective To analyze the clinical effect of fluoxetine in the treatment of patients with post-cerebral infarction depression ( PSD) and its influence on neurological rehabilitation.Methods From February 2017 to February 2018,92 PSD patients received treatment in the department of neurology of the Third People ＇s Hospital of Quzhou were included in the study.The patients were randomly divided into two groups according to the digital table , with 46 cases in each group.The control group was treated with specialist symptomatic therapy ,while the study group was treated with fluoxetine intervention for 4 weeks.The Hamilton anxiety scale (HAMD),neurological deficit scale (NIHSS) and daily living capacity scale (ADL) were used to evaluate the clinical effects of the two groups ,and the adverse reactions of the two groups were observed.Results One week before treatment,the HAMD,NIHSS and ADL scores of the study group were (28.37 ±2.18)points,(23.10 ±3.16)points and (40.61 ±3.52)points,respectively, which of the control group were (28.30 ±2.24)points,(22.91 ±3.20)points and (41.15 ±3.35)points,respectively, there were no statistically significant differences between the two groups (t＝0.223,1.522,0.761,all P＞0.05). After 2 weeks of treatment ,the HAMD,NIHSS and ADL scores of the study group were (21.08 ±2.33) points, (19.27 ±2.89) points and (49.26 ±2.88) points,respectively,which were higher than those of the control group [(24.15 ±2.43)points,(21.16 ±2.18)points,(44.26 ±2.54)points](t＝4.384,10.216,8.276,all P＜0.05). After 4 weeks of treatment ,the HAMD,NIHSS and ADL scores of the study group were (12.61 ±1.87) points, (10.12 ±1.30 ) points, (70.13 ±2.16) points, respectively, which were higher than those of the control group [(15.20 ±2.06)points,(17.45 ±2.66)points,(51.19 ±2.46)points](t＝7.273,18.283,5.371,all P＜0.05). The total effective rate of neurological recovery in the study group was 91.30%(42／46),the total effective rate of depression treatment was 84.78%(39／46),which in the control group were 76.09%(35／46) and 65.22%(30／46),respectively,the differences were statistically significant (χ2 ＝3.903,4.696,all P＜0.05).Conclusion The application of fluoxetine in the treatment of PSD can effectively improve the patients ＇depressive symptoms,promote the recovery of neurological function ,improve self-care ability,and has high safety.It has important clinical value.

Effect of fluoxetine intervention on clinical efficacy and neurological function rehabilitation in patients with depression after cerebral infarction / 中国基层医药

Objective@#To analyze the clinical effect of fluoxetine in the treatment of patients with post-cerebral infarction depression (PSD) and its influence on neurological rehabilitation.@*Methods@#From February 2017 to February 2018, 92 PSD patients received treatment in the department of neurology of the Third People's Hospital of Quzhou were included in the study.The patients were randomly divided into two groups according to the digital table, with 46 cases in each group.The control group was treated with specialist symptomatic therapy, while the study group was treated with fluoxetine intervention for 4 weeks.The Hamilton anxiety scale (HAMD), neurological deficit scale (NIHSS) and daily living capacity scale (ADL) were used to evaluate the clinical effects of the two groups, and the adverse reactions of the two groups were observed.@*Results@#One week before treatment, the HAMD, NIHSS and ADL scores of the study group were (28.37±2.18)points, (23.10±3.16)points and (40.61±3.52)points, respectively, which of the control group were (28.30±2.24)points, (22.91±3.20)points and (41.15±3.35)points, respectively, there were no statistically significant differences between the two groups (t=0.223, 1.522, 0.761, all P>0.05). After 2 weeks of treatment, the HAMD, NIHSS and ADL scores of the study group were (21.08±2.33)points, (19.27±2.89)points and (49.26±2.88)points, respectively, which were higher than those of the control group[(24.15±2.43)points, (21.16±2.18)points, (44.26±2.54)points](t=4.384, 10.216, 8.276, all P<0.05). After 4 weeks of treatment, the HAMD, NIHSS and ADL scores of the study group were (12.61±1.87)points, (10.12±1.30)points, (70.13±2.16)points, respectively, which were higher than those of the control group[(15.20±2.06)points, (17.45±2.66)points, (51.19±2.46)points](t=7.273, 18.283, 5.371, all P<0.05). The total effective rate of neurological recovery in the study group was 91.30%(42/46), the total effective rate of depression treatment was 84.78%(39/46), which in the control group were 76.09%(35/46) and 65.22%(30/46), respectively, the differences were statistically significant (χ2=3.903, 4.696, all P<0.05).@*Conclusion@#The application of fluoxetine in the treatment of PSD can effectively improve the patients' depressive symptoms, promote the recovery of neurological function, improve self-care ability, and has high safety.It has important clinical value.

Comparison of social function， adverse reaction and medication adherence of Paliperidone， Amisulpride and Olanzapine in patients with first-episode schizophrenia / 中国医师杂志

Objective To investigate the social function, adverse reaction and medication adherence of paliperidone, amisulpride, and olanzapine in patients with first episode schizophrenia.Methods A total of 96 patients with first episode of schizophrenia was randomly divided into three groups, with reference to random numbers, among which there were 32 in paliperidone group, 32 cases in amisulpride group, and 32 in olanzapine group.All the patients in all groups were assessed with negative and positive scale (PANSS), personal and social performance scale (PSP), drug attitude inventory (DAI) at baseline and the end of 6 months.Results (1) There was no significant difference in the therapeutic effect between three groups (P ＞ 0.05);(2) The scores of PSP and DAI were increased in three groups after treatment, and the difference was statistically significant compared to that before treatment (P ＜ 0.05).Conclusions Three drugs have similar efficacy in the treatment of first-episode schizophrenia, and there is no significant difference in improving medication compliance and social function.